Kiniksa Pharmaceuticals raised its full-year 2026 revenue guidance to $1.045 billion–$1.050 billion after strong third-quarter results, driven by sales of its recurrent pericarditis drug ARCALYST. ARCALYST revenue rose 58% year over year to $286 million. Operating income was $54.2 million and net income $47.3 million, both up significantly from a year earlier. Kiniksa ended the quarter with $568.8 million in cash, about $43 million more than the previous quarter. Penetration of the multiple-recurrence patient population reached 23%. Pivotal Phase 3 data for its next drug, KPL-387, is expected in the second half of 2027. A second candidate, KPL-1161, is on track to enter Phase 1 by the end of 2026.

KNSA stock climbs as traders eye leadership shift and Q3 call. TIM BOHEN - UPDATED OCT. 27, 2026, 4:47 PM ET Summarize this article Kiniksa Pharmaceuticals International plc stocks have been trading up by 22.98 percent amid bullish sentiment on its latest catalysts. Key takeaways. * Leadership reshuffle elevates Ross Moat to president and COO at Kiniksa Pharmaceuticals, signaling continuity and confidence in current execution. * Upcoming Kiniksa Pharmaceuticals conference call on 2026/10/27 will detail Q3 2026 financials and portfolio progress, setting up a clear volatility catalyst for KNSA. * Recent KNSA price action shows a sharp bounce from the low $70s to near $90, attracting momentum-focused traders. * Strong margins, rapid revenue growth, and low debt at Kiniksa Pharmaceuticals give KNSA a "quality but pricey" profile for active trading strategies. Live Update At 16:46:37 EDT: On Tuesday, October 27, 2026 Kiniksa Pharmaceuticals International plc stock [NASDAQ: KNSA] is trending up by 22.98%! Discover the key drivers behind this movement as well as its expert analysis in the detailed breakdown below. Quick financial overview. Kiniksa Pharmaceuticals International plc has been trading like a momentum story with real fundamentals behind it. The daily chart shows KNSA recovering from a 2026/10/26 close near $72.98 to about $89.20 on 2026/10/27. That's a big two-day surge off the lows, telling traders there is strong demand on dips. Under the hood, Kiniksa Pharmaceuticals posted quarterly revenue of about $243.6M, with gross profit near $132.0M. That translates to a hefty gross margin around 70.6%, which is high for any sector and shows pricing power. KNSA is also profitable, with net income of roughly $25.4M and an EBIT margin above 13%. For a growth-oriented pharma, that's not just "story stock" territory. The flip side is valuation. KNSA trades at a price-to-earnings ratio north of 80 and a price-to-sales ratio around 7.4. Those levels tell traders Kiniksa Pharmaceuticals is priced for strong future execution. Balance sheet strength helps: KNSA carries minimal debt, with total debt-to-equity near 0.01 and a current ratio around 3.9, giving the company room to weather volatility while it executes. Why traders are watching KNSA right now. Kiniksa Pharmaceuticals just handed traders a clean storyline: leadership continuity plus a near-term catalyst. The company promoted Ross Moat from executive vice president and chief operating officer to president and COO, effective immediately. That matters. For KNSA, this is not an outsider overhaul; it is an internal elevation that keeps the same operator in charge of execution, now with a bigger title and, likely, a louder voice in strategy. Traders care because leadership shifts at this level often precede a new phase of scaling. When a company like Kiniksa Pharmaceuticals gives more authority to a proven operator, it signals management likes how the machine is running. For KNSA, that can support confidence around future launches, lifecycle management, and cost discipline. At the same time, Kiniksa Pharmaceuticals has circled 2026/10/27 for its Q3 2026 conference call and webcast. That call will update traders on financial results and "portfolio execution" - code for how well the pipeline and marketed products are performing against plan. KNSA is already trading with a rich multiple, so the bar is high. Strong numbers and positive commentary can justify this week's run toward $90 and potentially squeeze shorts. A lukewarm update, on the other hand, can trigger a sharp pullback as fast money exits. The intraday tape on 2026/10/27 shows KNSA opening near $85 and grinding higher, with multiple tight consolidations between $88 and $90. That kind of steady bid, with higher lows throughout the day, often reflects funds and experienced traders building positions ahead of an expected catalyst. For short-term traders, KNSA is now a classic "event trade" - leadership story plus imminent earnings and pipeline color. Conclusion. Kiniksa Pharmaceuticals International plc is not trading like a quiet, forgotten biotech. KNSA just ripped from the low $70s back to the high $80s, right as the company reshapes its leadership team and heads into a key Q3 2026 update. The promotion of Ross Moat to president and COO tells traders that Kiniksa Pharmaceuticals wants stability at the top while it leans into portfolio execution. That kind of internal promotion usually reflects trust in the existing playbook, not a panic pivot. Financially, KNSA pairs high margins and positive cash flow with a stretched valuation. Kiniksa Pharmaceuticals is delivering revenue growth and solid returns on capital, but traders are paying up for that story. That's exactly the type of setup where earnings calls and portfolio comments matter more than usual. The 2026/10/27 conference call is likely to be a key moment where the KNSA chart either confirms this latest breakout or rejects it. For active traders, the game plan is about preparation, not prediction. As Tim Sykes likes to say, "The market doesn't owe you anything - you study, you plan, you execute, or you get run over." And as Tim Bohen, lead trainer with StocksToTrade says, "Time and experience have taught me that missed opportunities are part of the game. There's always another setup around the corner." KNSA is giving plenty to study right now: a sharp uptrend, a confident leadership move at Kiniksa Pharmaceuticals, and a hard catalyst dead ahead. This is prime territory for disciplined chart work, clear risk levels, and strict loss-cutting - not blind hope. This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Its coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, StocksToTrade, Inc. break down the events that can spark significant price action. Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead. Once your watchlist is set, take the next step and trade with confidence using StocksToTrade's robust platform. Don't miss out - grab your 14-day trial for just $7 and experience the edge you need to thrive in today's fast-paced markets. The hours when the stock market is closed to everyone except you. Every week, there's a stretch of time when the biggest players on Wall Street physically leave the market and don't come back until Monday. Meanwhile, news keeps breaking on hundreds of small, overlooked companies. Millionaire trader Tim Sykes calls that window the Weekend Gap, and it's the reason he can buy a small stock on a Friday afternoon, close his laptop, and check back Monday morning to see what happened while the market was shut. He recorded a free video walking through exactly how it works.